Next-Gen Novo Drug Shows 15.7 Percent Weight Loss

Published on March 10, 2025

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with Type 2 diabetes cut their weight by 15.7% after 68 weeks. The data is seen as crucial for the future potential for its experimental next-generation obesity…

Read Full Article (External Site)